A new monoclonal antibody drug, Nebokitug, has shown promising results for patients with Primary Sclerosing Cholangitis (PSC), a rare liver disease. Tested in a Phase-2 clinical trial across five countries, the drug was found safe and effective in reducing liver inflammation and fibrosis, offering hope beyond liver transplantation.